Pre-existing helminth infection impairs the efficacy of adjuvanted influenza vaccination in mice.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
09
2021
accepted:
21
03
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
The world health organization estimates that more than a quarter of the human population is infected with parasitic worms that are called helminths. Many helminths suppress the immune system of their hosts to prolong their survival. This helminth-induced immunosuppression "spills over" to unrelated antigens and can suppress the immune response to vaccination against other pathogens. Indeed, several human studies have reported a negative correlation between helminth infections and responses to vaccinations. Using mice that are infected with the parasitic nematode Litomosoides sigmodontis as a model for chronic human filarial infections, we reported previously that concurrent helminth infection impaired the vaccination-induced protection against the human pathogenic 2009 pandemic H1N1 influenza A virus (2009 pH1N1). Vaccinated, helminth-infected mice produced less neutralizing, influenza-specific antibodies than vaccinated naïve control mice. Consequently helminth-infected and vaccinated mice were not protected against a challenge infection with influenza virus but displayed high virus burden in the lung and a transient weight loss. In the current study we tried to improve the vaccination efficacy using vaccines that are licensed for humans. We either introduced a prime-boost vaccination regimen using the non-adjuvanted anti-influenza vaccine Begripal or employed the adjuvanted influenza vaccine Fluad. Although both strategies elevated the production of influenza-specific antibodies and protected mice from the transient weight loss that is caused by an influenza challenge infection, sterile immunity was not achieved. Helminth-infected vaccinated mice still had high virus burden in the lung while non-helminth-infected vaccinated mice rapidly cleared the virus. In summary we demonstrate that basic improvements of influenza vaccination regimen are not sufficient to confer sterile immunity on the background of helminth-induced immunosuppression, despite amelioration of pathology i.e. weight loss. Our findings highlight the risk of failed vaccinations in helminth-endemic areas, especially in light of the ongoing vaccination campaign to control the COVID-19 pandemic.
Identifiants
pubmed: 35358281
doi: 10.1371/journal.pone.0266456
pii: PONE-D-21-29265
pmc: PMC8970517
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266456Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2013 Apr 12;31(16):2050-6
pubmed: 23470236
Microbes Infect. 2005 Apr;7(4):612-8
pubmed: 15820154
Parasite Immunol. 2006 Oct;28(10):507-13
pubmed: 16965286
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1853-8
pubmed: 26755593
Science. 2009 Jul 10;325(5937):197-201
pubmed: 19465683
Clin Microbiol Infect. 2016 Jun;22(6):481-6
pubmed: 27172808
Immunol Rev. 2011 Jan;239(1):167-77
pubmed: 21198671
Vaccine. 2008 Jul 4;26(29-30):3690-5
pubmed: 18539369
Eur J Immunol. 2012 Apr;42(4):890-900
pubmed: 22161305
Cell Immunol. 1998 May 25;186(1):18-27
pubmed: 9637761
Hum Vaccin Immunother. 2018 Mar 4;14(3):550-564
pubmed: 29232151
Exp Parasitol. 2012 Sep;132(1):69-75
pubmed: 21723282
Vaccine. 2010 Apr 9;28(17):2917-23
pubmed: 20188676
Vaccine. 2006 Jun 12;24(24):5211-9
pubmed: 16675073
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6
pubmed: 18650390
Vet Parasitol. 2007 Aug 19;148(1):14-20
pubmed: 17587500
Clin Microbiol Rev. 2012 Oct;25(4):585-608
pubmed: 23034321
J Immunol. 2011 Oct 15;187(8):4088-99
pubmed: 21900178
ACS Pharmacol Transl Sci. 2020 Sep 30;3(5):1039-1041
pubmed: 33073203
Am J Pathol. 2011 Jul;179(1):230-9
pubmed: 21703405
Front Immunol. 2021 Dec 21;12:784141
pubmed: 34992602
Eur J Immunol. 2015 Sep;45(9):2568-81
pubmed: 26138667
PLoS Negl Trop Dis. 2014 Sep 25;8(9):e3170
pubmed: 25255463
Vaccine. 2021 Mar 15;39 Suppl 1:A15-A23
pubmed: 33422377
Adv Parasitol. 2019;103:11-30
pubmed: 30878055
J Infect Dis. 2007 Dec 1;196(11):1671-8
pubmed: 18008252
Parasite Immunol. 2020 Jul;42(7):e12708
pubmed: 32145033
Vaccine. 2008 Nov 5;26(47):5935-43
pubmed: 18804138
Vaccine. 2014 Sep 22;32(42):5405-10
pubmed: 25131738
Virulence. 2011 Nov-Dec;2(6):563-6
pubmed: 22030859
Front Immunol. 2013 May 16;4:114
pubmed: 23720661
Cell Rep. 2019 Nov 19;29(8):2243-2256.e4
pubmed: 31747598
Infect Immun. 2006 Apr;74(4):2138-44
pubmed: 16552043
Vaccine. 2011 Feb 17;29(9):1812-23
pubmed: 21215831
PLoS Negl Trop Dis. 2008 Apr 30;2(4):e217
pubmed: 18446236
Vaccine. 2019 Feb 14;37(8):1038-1045
pubmed: 30685251
Trends Parasitol. 2008 Jun;24(6):243-5
pubmed: 18450514
Infect Immun. 2001 Mar;69(3):1574-80
pubmed: 11179329
Vaccine. 2012 Dec 14;30(52):7621-4
pubmed: 23085365
Infect Immun. 2006 Apr;74(4):2277-85
pubmed: 16552058
Science. 2009 Jul 24;325(5939):484-7
pubmed: 19574347
Allergy. 2020 Mar;75(3):524-534
pubmed: 31187881
Vaccine. 2020 Jul 31;38(35):5582-5590
pubmed: 32616328
J Clin Invest. 2008 Apr;118(4):1311-21
pubmed: 18382743
Front Immunol. 2021 Jun 17;12:693269
pubmed: 34220854
Pediatrics. 2005 Jul;116(1):153-9
pubmed: 15995046